Point72 Asset Management
CRNX

Point72 Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Point72 Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
+46,381
New +$1.72M ﹤0.01% 2481
2026
Q1 		– Sell
-2,337,034
Closed -$109M – 3886
2025
Q4 		$109M Buy
2,337,034
+333,701
+17% +$14.9M 0.12% 161
2025
Q3 		$83.4M Buy
2,003,333
+5,172
+0.3% +$165K 0.14% 156
2025
Q2 		$57.5M Buy
1,998,161
+1,219,763
+157% +$37.7M 0.11% 217
2025
Q1 		$26.1M Sell
778,398
-2,010,541
-72% -$75.1M 0.06% 376
2024
Q4 		$143M Buy
2,788,939
+488,296
+21% +$27.3M 0.31% 62
2024
Q3 		$118M Sell
2,300,643
-480,213
-17% -$24.8M 0.3% 64
2024
Q2 		$125M Sell
2,780,856
-2,168,630
-44% -$100M 0.33% 69
2024
Q1 		$232M Buy
4,949,486
+1,532,586
+45% +$60M 0.56% 24
2023
Q4 		$122M Sell
3,416,900
-808,400
-19% -$24.8M 0.29% 63
2023
Q3 		$126M Buy
+4,225,300
New +$87.1M 0.37% 47
2023
Q2 		– Sell
-226,400
Closed -$3.64M – 2263
2023
Q1 		$3.64M Sell
226,400
-1,134,600
-83% -$21M 0.01% 851
2022
Q4 		$24.9M Buy
1,361,000
+50,800
+4% +$895K 0.08% 284
2022
Q3 		$25.7M Sell
1,310,200
-22,600
-2% -$461K 0.1% 263
2022
Q2 		$24.9M Buy
1,332,800
+126,462
+10% +$2.52M 0.1% 261
2022
Q1 		$26.5M Buy
1,206,338
+101,862
+9% +$2.06M 0.11% 257
2021
Q4 		$31.4M Buy
1,104,476
+654,676
+146% +$16.1M 0.13% 229
2021
Q3 		$9.47M Sell
449,800
-258,333
-36% -$5.4M 0.04% 504
2021
Q2 		$13.3M Sell
708,133
-566,867
-44% -$9.96M 0.06% 384
2021
Q1 		$19.5M Buy
1,275,000
+49,997
+4% +$775K 0.09% 272
2020
Q4 		$17.3M Buy
1,225,003
+713,015
+139% +$9.93M 0.08% 310
2020
Q3 		$8.02M Buy
511,988
+117,156
+30% +$1.79M 0.04% 458
2020
Q2 		$6.92M Buy
+394,832
New +$6.73M 0.05% 416
2020
Q1 		– Sell
-33,865
Closed -$850K – 821
2019
Q4 		$850K Sell
33,865
-98,135
-74% -$1.87M ﹤0.01% 733
2019
Q3 		$1.99M Buy
+132,000
New +$2.57M 0.01% 593

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management's CRNX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 46,381 shares worth $1.74M. The stake represents ﹤0.01% of the portfolio and ranks #2481 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in CRNX as recently as Q4 2025.

Point72 Asset Management first reported a position in CRNX in Q3 2019 and has held it in 25 quarters since. The position peaked at $232M in Q1 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Point72 Asset Management held 46,381 shares of Crinetics Pharmaceuticals worth $1.74M as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Point72 Asset Management position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #2481 holding.
  • Point72 Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2019 and has held it in 25 quarters since.
  • Point72 Asset Management's Crinetics Pharmaceuticals position peaked at $232M in Q1 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.